The stock is going up in anticipation of the Brilacidin un-blinding, which management announced would be in ~6 weeks and was very likely successful based on top-line results. A lot of investors feel the current CTIX price doesn't reflect the discounted market value of a more-likely successful Brilacidin antibiotic platform.
Market Data 
Markets 
AI
